The stem cell manufacturing market is projected to reach USD 21.8 billion by 2028 from USD 12.7 billion in 2023, at a CAGR of 11.3% during the forecast period. The key factors driving the growth of the global Stem Cell Manufacturing Market are growing investments in stem cell research and rising awareness about the therapeutic potency of stem cell products. However, significant operational costs associated with stem cell manufacturing and cell banking are expected to restrain market growth to a certain extent.
The market for stem cell manufacturing is highly fragmented, with key players strategizing to capture the majority of the market. Prominent players in the market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US), Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), Bio-Techne Corporation (US), HiMedia Laboratories (India), StemCell Technologies, Inc. (Canada), Miltenyi Biotec GmBH (Germany), PromoCell (Germany), Anterogen Co. Ltd. (South Korea), CellGenix GmBH (India), Pluristem Therapeutics Inc. (Israel), Daiichi Sankyo (Japan), Organogenesis Holdings Inc. (US), Vericel Corporation (US), and American Cryostem Corporation (US).
Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70743403
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher Scientific is a leading player in the stem cell manufacturing market, offering a comprehensive range of products and services tailored to the needs of this rapidly growing industry. With its strong presence in the life sciences domain, the company has been adopted for their products portfolio by researchers, developers, and manufacturers in the field of stem cell-based therapies and regenerative medicine.
Thermo Fisher Scientific provides a diverse portfolio of solutions specifically designed to support stem cell research and manufacturing processes. This includes advanced cell culture media and reagents that facilitate the expansion and differentiation of stem cells. These products are developed to meet the stringent quality requirements and regulatory standards necessary to produce safe and effective cell-based therapies.
In addition to cell culture media, Thermo Fisher Scientific offers a wide range of specialized laboratory equipment and technologies that enable efficient and precise handling of stem cells. This includes automated systems for cell processing, bioreactors for large-scale manufacturing, and cryopreservation solutions for long-term storage of stem cell lines.
MERCK KGaA (Germany)
Merck KGaA, also known as Merck Group, is a global science and technology company operating in the healthcare and life sciences sectors. With respect to the stem cell manufacturing market, Merck KGaA offers a comprehensive portfolio of products to support researchers and biopharmaceutical companies engaged in stem cell research and therapeutic development.
Merck KGaA provides a wide range of cell culture media, reagents, and tools that are essential for the cultivation and expansion of stem cells. Their products are designed to optimize cell growth, maintain cell pluripotency, and ensure the quality and consistency of stem cell cultures. These offerings include specialized media formulations, growth factors, cytokines, and supplements tailored to the unique requirements of stem cell culture systems.
Furthermore, Merck KGaA offers solutions for stem cell characterization and analysis. They provide a variety of tools, such as flow cytometry and gene expression analysis kits, to assess stem cell pluripotency, differentiation potential, and purity. These characterization tools enable researchers to monitor and optimize the quality of their stem cell populations.
LONZA GROUP (SWITZERLAND)
Lonza Group is one of the global leaders in the life sciences industry and has a significant presence in the stem cell manufacturing market. The company offers a comprehensive range of products to support the development, manufacturing, and commercialization of stem cell-based therapies and regenerative medicine.
Lonza provides end-to-end solutions for stem cell manufacturing, encompassing process development, cell line engineering, and large-scale production. Their expertise lies in the development and optimization of robust manufacturing processes that ensure the scalability, reproducibility, and quality of stem cell-based products.
Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=70743403
The company's extensive portfolio includes cell culture media, growth factors, and specialized reagents that are specifically designed to support the expansion, differentiation, and characterization of stem cells. Lonza's offerings are developed based on cutting-edge research and industry best practices, enabling their clients to meet regulatory requirements and achieve optimal outcomes in their stem cell manufacturing endeavors. In addition to products, Lonza also offers contract manufacturing services for stem cell-based therapies.
Furthermore, Lonza actively engages in collaborations and partnerships with academic institutions, biotech companies, and pharmaceutical companies to advance stem cell research and promote the translation of scientific discoveries into clinical applications. By fostering strategic alliances, Lonza aims to drive innovation in the field of stem cell manufacturing and contribute to the development of safe and effective therapies.
